Logo
x

Search

Subscribe Now

 Regulatory

PharmaShots Weekly Snapshots (November 04 – November 08, 2024)

PharmaShots Weekly Snapshots (November 04 – November 08, 2024)

  • November 8, 2024
AskBio’s AB-1003 Secures the US FDA’s Rare Pediatric Disease and Orphan Drug Designations to Treat Limb-Girdle Muscular Dystrophy Type 2I/R9

AskBio’s AB-1003 Secures the US FDA’s Rare Pediatric Disease and Orphan Drug Designations to Treat Limb-Girdle Muscular Dystrophy...

  • November 8, 2024
Dizal Reports the Regulatory Submission of Sunvozertinib to the US FDA for Treating R/R Non-Small Cell Lung Cancer

Dizal Reports the Regulatory Submission of Sunvozertinib to the US FDA for Treating R/R Non-Small Cell Lung Cancer

  • November 8, 2024
Cumberland Pharmaceuticals’ Ifetroban Secures the US FDA’s ODD and RPDD for Duchenne Muscular Dystrophy

Cumberland Pharmaceuticals’ Ifetroban Secures the US FDA’s ODD and RPDD for Duchenne Muscular Dystrophy

  • November 7, 2024
Leads Biolabs Secures the US FDA’s Orphan Drug Designation for LBL-034 to Treat Multiple Myeloma

Leads Biolabs Secures the US FDA’s Orphan Drug Designation for LBL-034 to Treat Multiple Myeloma

  • November 6, 2024
Sanofi and Regeneron Reports the EC’s Approval of Dupixent (Dupilumab) for Young Children with Eosinophilic Esophagitis (EoE)

Sanofi and Regeneron Reports the EC’s Approval of Dupixent (Dupilumab) for Young Children with Eosinophilic Esophagitis (EoE)

  • November 6, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.